ArticleBMC health services research2011
Lifetime economic burden of prostate cancer.
Article in BMC health services research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03561220 (A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Trial
- The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.Cancer · 2023Article
- Aptamers as Theragnostic Tools in Prostate Cancer.Biomolecules · 2022Review
- Treating the patient and not just the cancer: therapeutic burden in prostate cancer.Prostate cancer and prostatic diseases · 2021Review
- Basic social resource needs screening in the gynecologic oncology clinic: a quality improvement initiative.American journal of obstetrics and gynecology · 2020Article
- Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.Journal of managed care & specialty pharmacy · 2020Article
- Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.European urology focus · 2020Article
- Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.Journal of managed care & specialty pharmacy · 2019Article
- Article
- Medical Care Costs Associated With Cancer in Integrated Delivery Systems.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Article
- Total Lifetime and Cancer-related Costs for Elderly Patients Diagnosed With Anal Cancer in the United States.American journal of clinical oncology · 2018Article
- Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer.RSC advances · 2018Article
- Long-term costs and survival of prostate cancer: a population-based study.International urology and nephrology · 2017Article
- Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.JAMA oncology · 2017Article
- Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.Journal of managed care & specialty pharmacy · 2017Article
- Financial toxicity: a potential side effect of prostate cancer treatment among Australian men.European journal of cancer care · 2017Article
- [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].Der Urologe. Ausg. A · 2016Observational
- Phase-specific and lifetime costs of cancer care in Ontario, Canada.BMC cancer · 2016Article
- Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.Journal of managed care & specialty pharmacy · 2016Article
- Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.The oncologist · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is the most common cancer affecting men in the United States. The initial treatment and subsequent monitoring of PCa patients places a large burden on U.S. health care systems. The objectives of this study were to estimate the total and disease-related per-patient lifetime costs using a phase-based model of cancer care for PCa patients enrolled in Medicare.
methodsA model was developed to estimate life-time costs for patients diagnosed with PCa. Patients ≥ 65 years old and diagnosed with PCa between calendar years 1991-2002 were selected from the SEER database. Using SEER, we estimated survival times for PCa patients from diagnosis until death. The period of time patients contributed to treatment phases was determined using an algorithm designed to model the natural history of PCa. Costs were obtained from the US SEER-Medicare database and estimated during specific phases of care. Cost estimates were then combined with survival data to yield total and PCa-related life-time costs.
resultsOverall, the model estimated life-time costs of $110,520 (95% CI 110,324-110,739) per patient. PCa-related costs made up approximately 31% of total costs ($34,432).
conclusionsProstate cancer places a significant burden on U.S. health-care systems with average life-time PCa-related costs in excess of $30,000.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.